Thomas E. Hutson
YOU?
Author Swipe
View article: 11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis
11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis Open
Background Understanding how health-related quality of life (HRQOL) concerns vary by disease stage is essential for developing patient-reported outcome measures (PROMs) that reflect the lived experiences of individuals with renal cell carc…
View article: Cholinergic dysfunction in occupational manganese exposure
Cholinergic dysfunction in occupational manganese exposure Open
Higher Mn exposure is associated with lower cholinergic activity in multiple brain regions. Cholinergic function also mediates a portion of the relationship between Mn exposure and cognitive control performance. Caudate and cortical cholin…
View article: Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma Open
We successfully developed item subsets of the FKSI-23 questionnaire that address the multifaceted impact of localized and metastatic RCC on patients' HRQOL. These two clinical settings required distinct tools for optimal measurement of HRQ…
View article: Optimizing Pharmacotherapy During Implementation of Enhanced Recovery After Surgery (ERAS) in Ambulatory Urologic Oncology Surgery: Narrative Review
Optimizing Pharmacotherapy During Implementation of Enhanced Recovery After Surgery (ERAS) in Ambulatory Urologic Oncology Surgery: Narrative Review Open
Adapting Enhanced Recovery After Surgery (ERAS) protocols to the ambulatory surgery setting is an ongoing need. While all surgical procedures necessitate the need for recovery protocols, urologists looking to perform outpatient surgical on…
View article: Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study Open
Background The phase III TIVO-3 study demonstrated improvement in progression-free survival (PFS) with tivozanib compared with sorafenib in patients with 2-3 prior systemic regimens for metastatic renal cell carcinoma (mRCC). Methods The T…
View article: Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients Open
The estimated costs of managing VEGFR TKI class-effect AEs were lowest with tivozanib, and highest with lenvatinib and everolimus, indicating potentially differential healthcare resource burden by TKI regimen. The use of tivozanib in the 3…
View article: 5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605
5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605 Open
Background HC-7366 is a novel, orally administered, highly selective and potent activator of general control nonderepressible 2 (GCN2) kinase, a core regulator of metabolic stress through activation of the integrated stress response (ISR).…
View article: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms Open
Introduction. The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features inclu…
View article: Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms Open
[This corrects the article DOI: 10.3389/fonc.2023.1223282.].
View article: Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study Open
Background: The extent of tumor shrinkage has been deemed a predictor of survival for advanced/metastatic renal cell carcinoma (RCC), a disease with historically poor survival. Objective: To perform an exploratory analysis of overall survi…
View article: Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial Open
Background Tivozanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) with efficacy in advanced renal cell carcinoma (RCC). Long-term exploratory analyses from the TIVO-3 trial in relapsed/refr…
View article: Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms Open
Introduction The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features includ…
View article: Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab
Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab Open
.
View article: Plain Language Summary Looking at How Long Side Effects Last After Treatment with Axitinib is Stopped in People with Advanced Renal Cell Carcinoma
Plain Language Summary Looking at How Long Side Effects Last After Treatment with Axitinib is Stopped in People with Advanced Renal Cell Carcinoma Open
Axitinib is a medication that stops cancer cell growth by depriving the cancer cell of the nutrients and oxygen that it needs. Axitinib is used to treat advanced renal cell carcinoma (RCC), which is a type of kidney cancer that has spread …
View article: Supplementary Table 2 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Supplementary Table 2 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Open
Supplementary Table 2. Drug-related treatment emergent adverse events by CTCAE grade ({greater than or equal to} Grade 2) seen in the phase I component of the study.
View article: Data from The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
Data from The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma Open
Purpose: Inactivation of von Hippel-Lindau (VHL) gene in clear-cell renal cell carcinoma (RCC) leads to increased levels of hypoxia-inducible factors (HIF) and overexpression of HIF target genes, such as VEGF and others. VEGF-targeted agen…
View article: Supplementary Figure 2 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Supplementary Figure 2 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Open
Supplementary Figure 2. CONSORT diagram reflecting patients that received monotherapy with BNC105P after progression on everolimus monotherapy.
View article: Supplementary Figure 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Supplementary Figure 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Open
Supplementary Figure 1. PFS in patients receiving BNC105P monotherapy after crossover.
View article: Data from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Data from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Open
Purpose: BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy and safety of the combination were explored in patients with metastatic renal cell carci…
View article: Data from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Data from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Open
Purpose: BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy and safety of the combination were explored in patients with metastatic renal cell carci…
View article: Supplementary Table 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Supplementary Table 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Open
Supplementary Table 1. List of 40 exploratory plasma biomarkers investigated.
View article: Supplementary Figure 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Supplementary Figure 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Open
Supplementary Figure 1. PFS in patients receiving BNC105P monotherapy after crossover.
View article: Supplementary Table 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Supplementary Table 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Open
Supplementary Table 1. List of 40 exploratory plasma biomarkers investigated.
View article: Supplementary Methods and Figures and Tables from The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
Supplementary Methods and Figures and Tables from The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma Open
PDF file, 296K, The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Figure S1: Study design. Figure S2: Heatmap showing 4 potential …
View article: Data from The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
Data from The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma Open
Purpose: Inactivation of von Hippel-Lindau (VHL) gene in clear-cell renal cell carcinoma (RCC) leads to increased levels of hypoxia-inducible factors (HIF) and overexpression of HIF target genes, such as VEGF and others. VEGF-targeted agen…